BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced that its management will present at the 16th Annual LD Micro Invitational in Los Angeles, California. The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET. Interested parties can access live and archived webcasts on the investors section of the company's website at ir.biostemtechnologies.com.
The LD Micro Invitational is a key event for small-cap and micro-cap companies, providing a platform to showcase their business to investors. BioStem's participation underscores its commitment to increasing visibility within the investment community as it continues to advance its portfolio of allograft products. The company focuses on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue, leveraging proprietary technologies such as BioRetain®, CryoTek®, and SteriTek® to preserve the natural properties of these tissues for clinical use.
BioStem's allografts are utilized by clinicians across various specialties, and the company has built a national commercial footprint. Its quality management system and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). The company's product portfolio includes the Neox®, Clarix®, VENDAJE®, and American Amnion™ brands.
For investors and stakeholders, this presentation offers an opportunity to learn about BioStem's strategic direction, recent developments, and growth initiatives. The company's focus on innovation in regenerative medicine and its expanding clinical research initiatives are likely to be key topics. Additional information about BioStem is available on its website at www.biostemtechnologies.com, and the latest news can be found in the company's newsroom at https://tinyurl.com/bsemnewsroom.